Daily Ards Research Analysis
Three studies advance ARDS-related care: a machine learning model accurately predicts Helmet-CPAP failure using routine EMR, a VEGF/PEDF ratio strongly associates with in-hospital mortality in ARDS, and pretransplant blood transfusion is linked to markedly higher grade 3 primary graft dysfunction after lung transplant. Together, they highlight data-driven triage, biomarker-based risk stratification, and modifiable perioperative risks.
Summary
Three studies advance ARDS-related care: a machine learning model accurately predicts Helmet-CPAP failure using routine EMR, a VEGF/PEDF ratio strongly associates with in-hospital mortality in ARDS, and pretransplant blood transfusion is linked to markedly higher grade 3 primary graft dysfunction after lung transplant. Together, they highlight data-driven triage, biomarker-based risk stratification, and modifiable perioperative risks.
Research Themes
- Prognostic biomarkers in ARDS
- AI-driven prediction of noninvasive respiratory support failure
- Perioperative transfusion risk and primary graft dysfunction
Selected Articles
1. Machine learning-based forecast of Helmet-CPAP therapy failure in Acute Respiratory Distress Syndrome patients.
Using 622 EMR records with 38 features, SVM and neural network models predicted Helmet-CPAP failure in ARDS with high accuracy (up to 95.19%) and strong F1 scores (up to 88.61%). Key predictors included PaO2/FiO2, CRP, and oxygen saturation; performance remained robust after feature reduction.
Impact: Provides a timely AI tool to identify noninvasive support failure early, potentially reducing delayed intubation and improving outcomes.
Clinical Implications: Could support real-time triage for ARDS patients on Helmet-CPAP by flagging likely failure, prompting earlier escalation (e.g., intubation) and optimized resource allocation.
Key Findings
- SVM achieved 95.19% accuracy and 88.61% F1-score; neural networks achieved 94.65% accuracy and 87.18% F1-score.
- Key features driving predictions were PaO2/FiO2 ratio, C-reactive protein, and oxygen saturation; heart rate, WBC, and D-dimer were secondary.
- Model performance remained high with reduced feature sets (e.g., SVM with 23 features; XGBoost with 13 features).
Methodological Strengths
- Cross-validated ML models with train-test split on a real-world EMR dataset (n=622).
- Feature selection analyses demonstrating robust performance with reduced variables.
Limitations
- Single-center dataset without external validation, risking overfitting and limited generalizability.
- Retrospective design; no prospective clinical impact analysis or decision-curve evaluation.
Future Directions: External validation across diverse centers, prospective impact studies with clinician-in-the-loop deployment, and calibration/decision-curve analyses to quantify net benefit.
BACKGROUND AND OBJECTIVE: Helmet-Continuous Positive Airway Pressure (H-CPAP) is a non-invasive respiratory support that is used for the treatment of Acute Respiratory Distress Syndrome (ARDS), a severe medical condition diagnosed when symptoms like profound hypoxemia, pulmonary opacities on radiography, or unexplained respiratory failure are present. It can be classified as mild, moderate or severe. H-CPAP therapy is recommended as the initial treatment approach for mild ARDS. Even though the efficacy of H-CPAP in managing patients with moderate-to-severe hypoxemia remains unclear, its use has increased for these cases in response to the emergence of the COVID-19 Pandemic. Using the electronic medical records (EMR) from the Pulmonology Department of Vimercate Hospital, in this study we develop and evaluate a Machine Learning (ML) system able to predict the failure of H-CPAP therapy on ARDS patients. METHODS: The Vimercate Hospital EMR provides demographic information, blood tests, and vital parameters of all hospitalizations of patients who are treated with H-CPAP and diagnosed with ARDS. This data is used to create a dataset of 622 records and 38 features, with 70%-30% split between training and test sets. Different ML models such as SVM, XGBoost, Neural Network, Random Forest, and Logistic Regression are iteratively trained in a cross-validation fashion. We also apply a feature selection algorithm to improve predictions quality and reduce the number of features. RESULTS AND CONCLUSIONS: The SVM and Neural Network models proved to be the most effective, achieving final accuracies of 95.19% and 94.65%, respectively. In terms of F1-score, the models scored 88.61% and 87.18%, respectively. Additionally, the SVM and XGBoost models performed well with a reduced number of features (23 and 13, respectively). The PaO2/FiO2 Ratio, C-Reactive Protein, and O2 Saturation resulted as the most important features, followed by Heartbeats, White Blood Cells, and D-Dimer, in accordance with the clinical scientific literature.
2. Relationship between VEGF to PEDF ratio and in-hospital mortality in acute respiratory distress syndrome patients.
In a single-center retrospective cohort of 226 ARDS patients, the VEGF/PEDF ratio was independently associated with in-hospital mortality, achieving an AUC of 0.829 with 86.3% sensitivity and 68.0% specificity. Findings highlight angiogenic balance as a prognostic axis in ARDS.
Impact: Introduces a biologically plausible, easily measurable ratio that may refine ARDS risk stratification and guide monitoring or trial enrichment.
Clinical Implications: VEGF/PEDF ratio could be integrated into early ARDS assessment to identify high-risk patients for intensified monitoring or targeted interventions.
Key Findings
- Among 226 ARDS patients, the VEGF/PEDF ratio was strongly associated with in-hospital mortality in multivariable analysis.
- Diagnostic performance: AUC 0.829 (95% CI 0.772–0.885; P<0.001), sensitivity 86.3%, specificity 68.0%.
- Non-survivors were older and had worse respiratory and biochemical profiles compared with survivors.
Methodological Strengths
- Clear outcome (in-hospital mortality) with multivariable stepwise logistic regression.
- Quantified prognostic performance with AUC and sensitivity/specificity.
Limitations
- Single-center retrospective design limits generalizability and causal inference.
- No external validation or comparison against established ARDS prognostic scores.
Future Directions: External validation, prospective evaluation of clinical utility, and mechanistic studies linking angiogenic balance to ARDS pathobiology.
Acute respiratory distress syndrome (ARDS) has a high mortality rate worldwide; thus, identifying death risk factors related to ARDS is critical for risk stratification in patients with ARDS. In the present study, we conducted a single-center retrospective cohort analysis. Out of 278 patients with ARDS admitted from January 2016 to June 2022, 226 were included in this study. The patients were classified based on whether they were alive or dead during hospitalization. Their demographic and laboratory data and results were analyzed by performing a standard statistical analysis. Patients in the death group were older, with worse respiratory functions and blood biochemistry than those in the non-death group. Moreover, statistically significant differences were observed in the levels of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) between the two groups. Multivariate stepwise logistic regression analysis showed that the VEGF/PEDF ratio was strongly associated with the risk of death. The area under the curve of the VEGF/PEDF ratio was 0.829 (95% confidence interval: 0.772-0.885; P < 0.001), sensitivity was 86.3%, and specificity was 68.0%. Therefore, a VEGF/PEDF ratio is positively correlated with the risk of death in patients with ARDS.
3. The Risk of Pretransplant Blood Transfusion for Primary Graft Dysfunction After Lung Transplant.
In 206 consecutive lung transplants, pretransplant transfusion was strongly associated with increased grade 3 PGD (48.5% vs 6.9%). These findings raise concern about modifiable perioperative exposures that may exacerbate PGD risk.
Impact: Identifies a potentially modifiable risk factor for severe PGD, an ARDS-like syndrome and major cause of mortality after lung transplantation.
Clinical Implications: Supports minimizing nonessential transfusions before lung transplant and prompts careful risk-benefit assessment when pretransplant transfusion is considered.
Key Findings
- Among 206 lung transplants, PGD grade 3 occurred in 13.2% (n=28).
- Pretransplant transfusion within weeks of transplant was associated with markedly higher PGD grade 3 incidence (48.5% vs 6.9%).
- Data encompassed patient characteristics, pretransplant labs, transfusion exposures, and perioperative outcomes.
Methodological Strengths
- Consecutive cohort from a high-volume academic center with standardized PGD grading.
- Detailed capture of pretransplant transfusion timing and exposures.
Limitations
- Single-center retrospective design with potential confounding and incomplete adjustment.
- The abstract does not report adjusted effect sizes or p-values, limiting quantitative interpretation.
Future Directions: Prospective multicenter validation and mechanistic studies on transfusion-related lung injury pathways in transplant recipients.
BACKGROUND: Primary graft dysfunction (PGD) is the leading cause of short- and long-term mortality associated with lung transplantation. The impact of pretransplantation blood transfusions for recipients is not fully elucidated. METHODS: This is a retrospective review of 206 consecutive lung transplantations performed at a single academic center (Northwestern University Feinberg School of Medicine, Chicago, IL) from January 2018 to July 2022. Data on patient characteristics, pretransplantation laboratory values, transfusion requirements, and intraoperative and postoperative outcomes were collected. RESULTS: PGD grade 3 (PGD 3) occurred in 13.2% of the cohort (n = 28). A total of 33 patients received a blood transfusion within 4 weeks, whereas 21 patients received a blood transfusion a week before their lung transplant. Pretransplantation transfusions were strongly associated with a higher incidence of PGD 3 (48.5% vs 6.9%; CONCLUSIONS: Pretransplantation blood transfusions could be associated with a higher rate of PGD. The findings indicated the potential risks of pretransplantation blood transfusions in lung transplant recipients.